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Genetically modified recombinant poxviruses have shown
promise in preclinical models of cancer immunotherapy
due to their ability to induce effective cell-mediated
immunity against target tumor-associated antigens
(TAA). One such vector, recombinant Modified Vaccinia
Ankara (MVA), is capable of expressing foreign genes in
infected host cells. MVA is replication restricted in most
mammalian cells exemplifying a unique safety profile. We
have demonstrated that the interleukin-13 receptor a2
(IL-13Ra2) is selectively expressed in various solid
tumors but not in normal tissues making it a promising
TAA. Prophylactic and therapeutic vaccination with a
plasmid vector expressing IL-13Ra2 caused only partial
regression of established tumors [1], suggesting that host
immune responses against IL-13Ra2 needed further
enhancement. Thus, we constructed a recombinant MVA
(rMVA-IL13Ra2) expressing both IL-13Ra2 and a green
fluorescent protein (GFP) reporter gene. Purified virus
titration by immunostaining using anti-vaccinia antibody
and anti-IL-13Ra2 antibody confirmed the identity and
purity of the recombinant MVA. Western Blot analysis
showed the presence of IL-13Ra2 protein (65 kDa). Flow
cytometric analysis of IL-13Ra2 negative T98G glioma
cells infected with rMVA-IL13Ra2 virus (T98G-IL13Ra2)
demonstrated surface expression of IL-13Ra2, indicating
the infectivity potential of the recombinant virus. Incuba-
tion of T98G-IL13Ra2 cells with varying concentrations
(0-100 ng/ml) of IL13-PE (interleukin-13 fused to truncated
Pseudomonas exotoxin [2] resulted in depletion of GFP+
T98G-IL13Ra2 cells in a concentration-dependent manner.
Higher concentrations of IL13-PE (10-1000 ng/ml) also
inhibited the protein synthesis in T98G-IL13Ra2 compared
to cells infected with control pLW44-MVA. We further
observed that IL13-PE treatment of rMVA-IL13Ra2
infected chicken fibroblast, DF-1 cells led to a reduction in
virus titer compared to untreated cells. These results indi-
cate that rMVA-IL13Ra2 virus can successfully infect
mammalian cells and express IL-13Ra2 in a biologically
active form on the cell surface. The immunization studies
of rMVA-IL13Ra2 are ongoing in a syngeneic mouse
model of metastatic breast carcinoma. Based on in vitro
results, we expect the rMVA-IL13Ra2 to be a useful agent
in tumor immunotherapy as a vaccine alone and in combi-
nation with other therapeutic agents to eradicate metastatic
tumors.
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